Parotid Gland Tumor Found in 38-Year-Old Man

Poll

A 38-year-old man presents with a parotid gland tumor. After the biopsy, what is your diagnosis?

A 38-year-old man presents with a parotid gland tumor. What is your diagnosis after looking at the pathology slide below?

What is your diagnosis?

A. Mucoepidermoid carcinoma
B. Warthin’s tumor
C. Mixed tumor
D. Adenocarcinoma
Recent Videos
Adding bortezomib to Isa-Rd triplet therapy enhanced MRD-negative responses in patients with transplant-ineligible multiple myeloma.
Isatuximab plus VRd triplet therapy did not significantly increase toxicity in patients with transplant-ineligible multiple myeloma in the IMROZ trial.
Isatuximab quadruplet therapy for patients with multiple myeloma prolonged progression-free survival when compared with VRd triplet therapy.
Retrospective study data show that patients with inflammatory bowel disease may not require modification of standard radiotherapy for pelvic malignancies.
Prospective trial data may help guide treatment planning for patients with inflammatory bowel disease planning to undergo radiotherapy.
Samantha Shenoy, NP, MSN, suggests that support groups may help comfort patients experiencing adverse effects negatively impacting quality of life.
Related Content
Concurrent chemoradiation yielded similar contralateral breast recurrence outcomes vs a sequential approach in early-stage breast cancer.

Adjuvant cCRT Improves Disease Control, But Increases AEs in Breast Cancer

Gina Mauro
October 3rd 2024
Article

Concurrent chemoradiation yielded similar contralateral breast recurrence outcomes vs a sequential approach in early-stage breast cancer.

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma

James R. Berenson, MD, FACP
September 30th 2024
Podcast

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Multiple myeloma

HDP-101 Demonstrates Preliminary Efficacy in R/R Multiple Myeloma

Russ Conroy
October 2nd 2024
Article

Investigators anticipate launching the dose-expansion portion of the phase 1 HDP-101-01 trial in 2025.

Investigators of the Gliofocus trial look to set a clinically relevant “benchmark” in the glioblastoma field, according to Nader Sanai, MD.

Advancing Glioblastoma Research Through a Phase 3 Niraparib Trial

Nader Sanai, MD
September 23rd 2024
Podcast

Investigators of the Gliofocus trial look to set a clinically relevant “benchmark” in the glioblastoma field, according to Nader Sanai, MD.

Adaptive Radiotherapy Modality Appears Safe, Feasible in High-Grade Glioma | Image Credit: © Dr_Microbe - stock.adobe.com.

Adaptive Radiotherapy Modality Appears Safe, Feasible in High-Grade Glioma

Russ Conroy
October 1st 2024
Article

UNITED is the first trial to assess MR-guided weekly adaptive on-line and real-time radiotherapy with clinical target volume margin reductions.

Data from DESTINY-Breast06 support the priority review designation for T-DXd as a treatment for HER2-low or HER2-ultralow breast cancer.

T-DXd Earns FDA Priority Review in Pretreated HER2-Low Breast Cancer

Russ Conroy
October 1st 2024
Article

Data from DESTINY-Breast06 support the priority review designation for T-DXd as a treatment for HER2-low or HER2-ultralow breast cancer.